Home › Trial NCT01956695
Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma
- Trial IDNCT01956695
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorInstitut Curie
- Enrollment45
- Start date2013-09-18
- ConditionsLymphoma · Relapse
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.